Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics ...Middle East

Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed...

Hence then, the article about tissue dynamics and galmed pharmaceuticals to develop human centered chronic cardiac fibrosis platform to advance aramchol based therapeutics was published today ( Wednesday 06/05/2026 - 02:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics )

Also on site :

• RECYCLEXPERT FZE Strengthens Leadership in Data Destruction UAE and GCC with Certified Secure ITAD Services
• Amazon's 'Long-Lasting' $20 Solar Edison String Lights Add ‘Excellent Ambient Lighting’ to Any Backyard
• Iconic ’90s Actor From ‘The Terminator’ Turns 86